睿昂基因(688217.SH)：2025年净亏损4988.36万元

Core Viewpoint - Ruiang Gene (688217.SH) reported a significant decline in its financial performance for the year 2025, with all key metrics showing increased losses compared to the previous year [1] Financial Performance Summary - The company achieved total operating revenue of 173.9999 million yuan, a decrease of 28.19% compared to the same period last year [1] - Operating profit was -53.5036 million yuan, with an increase in losses of 25.0818 million yuan year-on-year [1] - Total profit amounted to -54.4323 million yuan, reflecting an increase in losses of 25.9578 million yuan compared to the previous year [1] - The net profit attributable to the parent company's shareholders was -49.8836 million yuan, with losses increasing by 34.1191 million yuan year-on-year [1] - The net profit attributable to the parent company's shareholders, excluding non-recurring gains and losses, was -58.2004 million yuan, with an increase in losses of 38.9528 million yuan compared to the previous year [1] - Basic earnings per share were -0.90 yuan, with losses increasing by 0.62 yuan year-on-year [1]